3 results
Approved WMORecruiting
The primary aim of the trial is to demonstrate the non-inferiority of CSL222 (formerly AMT-061) (2 × 1013 gc/kg) during the 52 weeks following establishment of stable factor IX expression (months 6 to 18) post-treatment (CSL222 (formerly AMT-061))…
Approved WMOCompleted
· To evaluate the effect of zibotentan anddapagliflozin in combination and alone versusplacebo on UACR.
Approved WMOPending
The primary objective is to influence amygdala and ventral striatum neuronal activity, thereby changing their influence on consequent approach/avoidance decisions, as indicated with left or right button presses.